Clinical Trial Update: To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the relative bioavailability of divalproex sodium 500 mg delayed-release tablets under fasting conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• divalproex sodium delayed-release tablets, 500 mg (divalproex sodium)

Snippet

Sponsor: Sandoz | Conditions: Epilepsy, Bipolar Disorder | Phase 1 | Status: COMPLETED